Literature DB >> 21211537

Preclinical jockeying on the translational track of adenosine A2A receptors.

Melita T Barkhoudarian1, Michael A Schwarzschild.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21211537      PMCID： PMC3073659          DOI： 10.1016/j.expneurol.2010.12.022

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  43 in total

1.  Adenosine A2A receptors and depression.

Authors:  Malika El Yacoubi; Jean Costentin; Jean-Marie Vaugeois
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 2.  Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Authors:  Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

3.  An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers.

Authors:  David J Brooks; Spyridon Papapetropoulos; Francois Vandenhende; Davorka Tomic; Ping He; Alex Coppell; Gilmore O'Neill
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

Review 4.  Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Authors:  S Ferré; I Diamond; S R Goldberg; L Yao; S M O Hourani; Z L Huang; Y Urade; I Kitchen
Journal:  Prog Neurobiol       Date:  2007-05-01       Impact factor: 11.685

Review 5.  Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders.

Authors:  Christa E Müller; Sergi Ferré
Journal:  Recent Pat CNS Drug Discov       Date:  2007-01

Review 6.  Caffeine and coffee as therapeutics against Alzheimer's disease.

Authors:  Gary W Arendash; Chuanhai Cao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.

Authors:  Danqing Xiao; Elena Bastia; Yue-Hang Xu; Caroline L Benn; Jang-Ho J Cha; Tracy S Peterson; Jiang-Fan Chen; Michael A Schwarzschild
Journal:  J Neurosci       Date:  2006-12-27       Impact factor: 6.167

8.  Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Authors:  Kevin J Black; Jonathan M Koller; Meghan C Campbell; Debra A Gusnard; Stephen I Bandak
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

9.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

Authors:  R Grondin; P J Bédard; A Hadj Tahar; L Grégoire; A Mori; H Kase
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

Review 10.  Pathophysiological roles for purines: adenosine, caffeine and urate.

Authors:  Micaela Morelli; Anna R Carta; Anil Kachroo; Michael A Schwarzschild
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453
View more
  6 in total

1.  Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

2.  Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease.

Authors:  Stefka Gyoneva; Lauren Shapiro; Carlos Lazo; Ethel Garnier-Amblard; Yoland Smith; Gary W Miller; Stephen F Traynelis
Journal:  Neurobiol Dis       Date:  2014-03-13       Impact factor: 5.996

3.  Systemic inflammation regulates microglial responses to tissue damage in vivo.

Authors:  Stefka Gyoneva; Dimitrios Davalos; Dipankar Biswas; Sharon A Swanger; Ethel Garnier-Amblard; Francis Loth; Katerina Akassoglou; Stephen F Traynelis
Journal:  Glia       Date:  2014-05-07       Impact factor: 7.452

Review 4.  The emerging role of nutrition in Parkinson's disease.

Authors:  Stacey E Seidl; Jose A Santiago; Hope Bilyk; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2014-03-07       Impact factor: 5.750

Review 5.  Life style and Parkinson's disease.

Authors:  Heinz Reichmann; Ilona Csoti; Jiri Koschel; Stefan Lorenzl; Christoph Schrader; Juergen Winkler; Ullrich Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2022-05-23       Impact factor: 3.850

Review 6.  The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease.

Authors:  Jiang-Fan Chen; Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2020-03-31       Impact factor: 3.765
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.